DIAGNOSTICS | PROTEIN SERVICES

+49 231 9742 6300 | info@protagen.de

Home
- Protagen Protein Services
- Protagen Diagnostics
Protein Characterization
Biopharmaceuticals
Biosimilars
- Adalimumab
- Bevacizumab
- Cetuximab
- Erythropoietin
- Etanercept
- Factor VIII
- G-CSF
- Infliximab
- Natalizumab
- Rituximab
- Trastuzumab
Analytical Methods
Quality
Company

Company

Investors

Investors

Investors in Protagen AG are:

S-Venture Capital Dortmund GmbH
MIG Fonds
Kreditanstalt für Wiederaufbau (KfW)
S-Capital Dortmund GmbH & Co. KG
NRW.BANK

Company

News & Press
Events
- Events Archive
Management
Board of Directors
Partners and Network
Investors
Career
- Working at Protagen
- Job Opportunities
Contact

Downloads

- Information & Brochures
- Publications
  - Protein Services
  - Bio-IT

Protein Characterization

Biopharmaceuticals

Biosimilars

Analytical Methods

Company

Protein Quantification
Protein Primary Structure
Glycosylation
Protein Modification
Bioassay
Protein Impurities

Comparability
Stability
Release Testing
GMP Protein Analysis
ICH Q6B
Antibodies
Biosimilars

Adalimumab
Bevacizumab
Cetuximab
Erythropoietin
Etanercept
Factor VIII
G-CSF
Infliximab
Natalizumab
Rituximab
Trastuzumab

Mass Spectrometry
Bio-IT in Mass Spectrometry
Liquid Chromatography
Electrophoresis
List of instrumentation

Management
Board of Directors
Partners and Network
Investors
Career
Contact

© 1997-2012 Protagen AG | Otto-Hahn-Str. 15 | 44227 Dortmund | Germany | +49 231 9742 6300 | info@protagen.de | Sitemap
HRB: 15399 | VAT ID: DE 207221039